Azenta, Inc. has announced a strategic partnership with Frenova, a division of Fresenius Medical Care, and Nephronomics to support the MyReason® genomics research program. This collaboration is a significant step toward advancing precision medicine for cardio-kidney-metabolic (CKM) diseases, which are often complex and difficult to treat. Frenova's MyReason program is a large-scale initiative that has already enrolled over 35,000 participants and aims to reach 50,000. It's building a vast database of genomic and clinical data from patients with CKM diseases.



Azenta's role in this partnership is crucial, as it will leverage its expertise in multiomics analysis and sample management. Specifically, Azenta will provide genomic sequencing services through its GENEWIZ brand and handle long-term biospecimen storage within its global biorepository network. This ensures the integrity of the valuable samples and the quality of the generated data. The MyReason dataset is the foundation of the Nephronomics Atlas, a comprehensive resource that Nephronomics, a Renal Precision Medicine company, will use to drive its research. By applying proprietary AI/machine learning models to this data, Nephronomics intends to identify new disease subtypes, protective genetic variants, and novel therapeutic targets. This powerful collaboration combines Frenova's extensive clinical network and expertise, Azenta's state-of-the-art genomic solutions, and Nephronomics's data analysis capabilities to unlock new insights that could lead to revolutionary therapies and diagnostics for CKM diseases.